secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0000950170-24-033464
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest reports FY2023 net loss $29.5M; positive Phase 1b/2 HCC data for TPST-1120
--------------------------------------------------------------------------------

- Net loss $29.5M ($1.91/sh) vs $35.7M in 2022; cash $39.2M, runway into Q2 2025.
- TPST-1120 triplet arm: 30% cORR vs 13.3% control; OS HR 0.59 favoring TPST-1120 in first-line HCC.
- Plan to advance TPST-1120 into pivotal Phase 3 in HCC; TPST-1495 into Phase 2 FAP (pending NCI).
- R&D expenses down to $17.5M from $22.5M, primarily due to lower CRO costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/0000950170-24-033464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017024033464/tpst-20240319.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-033464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer